Evidence map›Paper›PMID 32039400›Full record

ReviewJHEP reports : innovation in hepatology2019

Management of patients with pre-therapeutic advanced liver fibrosis following HCV eradication.

Pierre Nahon, Nathalie Ganne-Carrié

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in JHEP reports : innovation in hepatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. After the Storm: Persistent Molecular Alterations Following HCV Cure.International journal of molecular sciences · 2024
    Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. The changing face of hepatology.JHEP reports : innovation in hepatology · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Pierre NahonAP-HP, Hôpital Jean Verdier, Liver Unit, Bondy, France.
Nathalie Ganne-CarriéAP-HP, Hôpital Jean Verdier, Liver Unit, Bondy, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with HCV-related bridging fibrosis or cirrhosis remain at risk of developing life-threatening complications even after achieving a sustained virological response. Although it is reduced, the risk of liver-related events in these patients justifies their inclusion in surveillance programmes dedicated to the early detection of hepatocellular carcinoma and the screening for portal hypertension. Biochemical parameters or non-invasive tests might indicate the potential progression of liver injury despite viral clearance. Specific attention must be focused on the management of comorbidities, while dedicated educational programmes must be encouraged to increase compliance and commitment to surveillance. Better knowledge of the long-term evolution of these patients, who now live longer, is essential to improve risk stratification and refine screening strategies in this growing population.

Indexed as

AFP, alpha-fetoproteinALT, alanine aminotransferaseAPRI, AST-to-platelet ratio indexAST, aspartate aminotransferaseDAAs, direct-acting antiviralsEHC, extrahepatic cancerFIB-4, fibrosis-4HCC, hepatocellular carcinomaHCVHepatocellular carcinomaHR, hazard ratioLiver failureLSM, liver stiffness measurementMACEs, major adverse cardiovascular eventsPHT, portal hypertensionPortal hypertensionSMR, standardised mortality ratiosurveillanceSVRSVR, sustained virological response

Identifiers

PMID32039400
PMCPMC7005771

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.